A 16-year follow-up of 861 older adults compared how well GrimAge2, brain volume, respiratory function, and organ clocks predict all-cause mortality risk.
On October 2, 2026, The Longevity Leaders reported on a new publication in Wiley’s Aging Cell that evaluated several biomarkers for mortality risk. The report detailed a 16-year follow-up study analyzing which molecular and physiological tests best predict outcomes in older adults.
The 16-year follow-up of 861 older adults evaluated GrimAge2 alongside brain and gray-matter volume. Researchers also compared respiratory function, cognitive performance, and plasma proteomic organ clocks. The team evaluated how each specific domain predicted all-cause mortality over the observation period. The primary conclusion was that GrimAge2 and brain volume predicted mortality more strongly than the proteomic organ clocks. Respiratory function and cognitive performance also outperformed the protein panels, suggesting that combining diverse physiological indicators provides a stronger predictive model than a single organ-specific metric.
This study was conducted in humans, analyzing a cohort of 861 older adults.
While single biological clocks gain significant media attention, the reality of human physiology is deeply complex. The 861-person study highlights how different aspects of aging progress at different rates within the same individual. Stanford Medicine explains that GrimAge is designed to reflect mortality or future disease risk, not simply chronological or biological age. This distinction is crucial when interpreting how different tests rank health status over time, a major focus within biological age testing.
By focusing on health outcomes rather than just the passage of time, specific risk clocks provide useful benchmarks for clinical studies. This design choice explains why GrimAge2 performed strongly in tracking all-cause mortality. The test aims to measure the biological toll of aging rather than just counting calendar years. This makes it a valuable tool for understanding systemic physiological deterioration over a long period.
The Longevity Leaders summary also detailed specific protein measurements from the cohort data. It notes that protein measurements can reflect aging in specific organs quite accurately. The analysis evaluated 9,703 protein targets to see which ones correlated with survival over the study window. The report stated that 368 of those protein targets were ultimately linked to mortality in the older adult group.
Among these significant targets, GDF15, WFDC2, and TIMP1 emerged as the leading signals. The researchers found that elevated-risk proteins clustered around immune signaling pathways. Conversely, the protective proteins mapped to areas involving genomic stability and cellular maintenance. However, it is essential to remember that these are predictive associations rather than proven causal mechanisms.
It is easy to focus entirely on modern molecular tests while ignoring fundamental physiological measurements. However, the finding that respiratory function strongly predicts mortality aligns with long-standing principles in longevity research. Lung function impacts oxygen delivery to every single cell and organ system in the body. When respiratory capacity diminishes, the resulting physiological stress affects systemic health significantly.
In the 16-year follow-up of the 861 older adults, traditional lung capacity testing proved remarkably resilient as a mortality predictor. The fact that a physical respiratory test outperformed complex plasma proteomic organ clocks is a vital takeaway. It illustrates why traditional physiological tests remain highly relevant today for clinical assessments. Measurements of lung capacity and physical resilience still hold immense value alongside modern molecular evaluations.
Alongside molecular tests, the researchers evaluated physical changes in the brain over the 16-year period. Tracking brain and gray-matter volume offers a direct look at structural organ health in older adults. Unlike a plasma protein test, a brain scan visualizes the actual tissue loss associated with aging and cognitive decline. The report indicates that these structural brain measurements were among the strongest predictors of mortality.
This finding reinforces the idea that visible structural degradation carries significant weight in long-term health forecasting. While blood tests provide real-time molecular data, imaging reveals cumulative physical changes within the central nervous system. Combining these structural metrics with epigenetic data could theoretically offer a much broader view of a patient's vulnerability. It highlights the absolute importance of maintaining whole-organ structural health alongside basic cellular optimization.
Cognitive performance was another major physiological domain evaluated in the 861-person cohort. Testing how well the brain functions is just as important as measuring its physical size. Cognitive tests measure executive function, memory retention, and processing speed. The results showed that cognitive performance strongly predicted all-cause mortality over the 16-year timeframe.
This strong predictive power suggests that cognitive decline is deeply intertwined with systemic physical deterioration. When brain function slows down, it often signals wider physiological stress that affects the entire body. Therefore, maintaining cognitive sharpness is not merely about preserving an individual's quality of life. It serves as a vital biomarker for overall survival and systemic physiological resilience.
One of the most notable findings was the relative underperformance of plasma proteomic organ clocks. These clocks analyze specific proteins in the blood to estimate the biological age of individual organ systems. While the theory behind organ-specific testing is highly promising, the practical execution remains incredibly complex. The 16-year follow-up data suggested these proteomic models did not predict mortality as strongly as the other methods.
This does not mean that protein testing is useless for evaluating long-term healthspan. The Stanford explainer clarifies that protein measurements can reflect aging in specific, localized organ systems quite accurately. However, a localized organ issue might not immediately translate into a broader, immediate risk of all-cause mortality. Systemic metrics like respiratory capacity or GrimAge2 might simply capture a wider array of fatal risk factors.
A central challenge in evaluating longevity science is distinguishing between a predictive association and a definitive health prognosis. The reported data indicates that some measures predicted outcomes more strongly than others during the study. However, the news entry did not establish whether any of these measures improve clinical decisions beyond conventional risk factors. Consumers should not view a GrimAge2 result or a protein panel as a fixed, unchangeable lifespan prediction.
Stanford Medicine notes that organ-specific protein measures capture entirely different aspects of aging than DNA methylation tests. This explains why an epigenetic clock, respiratory function, and cognition tests might rank people differently. A multifaceted approach to testing likely yields a more accurate, comprehensive understanding of physiological decline. Still, no single metric currently serves as an absolute biological deadline.
The most critical takeaway from this 16-year follow-up is the strict boundary between prediction and direct causation. A biological measure might accurately forecast mortality risk without actually causing the underlying physiological decline. The news entry states clearly that these are predictive comparisons rather than evidence of direct causality. Altering a biological clock score through lifestyle interventions does not automatically guarantee a longer, healthier life.
This vital distinction is the primary reason why clinical applications often lag far behind laboratory research. An epigenetic test might flag a high-risk profile, but it cannot always pinpoint the exact physiological failure points. That is why combining GrimAge2 with functional assessments like respiratory tests yields a more accurate clinical picture. Until causation is proven, these tools remain sophisticated observational instruments rather than direct therapeutic targets.
While the summary from The Longevity Leaders presents interesting comparative data, it omits critical details necessary for full scientific verification. Until the original Aging Cell publication can be reviewed directly, several major weaknesses restrict how these findings should be applied.
Before these comparative rankings can influence medical guidelines, independent researchers must validate these specific models in separate populations with fully disclosed statistical methods.
Once readers understand that multiple physiological and molecular measures predict mortality differently, the next crucial step is determining how to evaluate these metrics safely. AgeAmaze resolves the difficulty distinguishing animal research from human evidence, helping you interpret complex longitudinal studies so you can assess emerging diagnostics with clear scientific context. Read the research
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
